The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. SOPHiA UNITY is the global consortium announced at ASCO by SOPHiA GENETICS that connects best-in-class healthcare institutio ...

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland, Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and ...

Core Viewpoint - SOPHiA GENETICS SA (SOPH) has experienced a significant decline of 30.5% over the past four weeks, but it is now positioned for a potential trend reversal due to being in oversold territory and positive earnings expectations from Wall Street analysts [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2] - SOPH's current RSI reading is 17.38, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for SOPH will improve, with a reported increase of 8.7% in the consensus EPS estimate over the last 30 days [6] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [6] Group 3: Analyst Ratings - SOPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]

SOPHiA GENETICS SA (SOPH) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Individual inv ...

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 17.86%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.21, delivering a surprise of 16%. Over the last four quarters, the company has surpas ...

Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents | --- | --- | |-------|-----------------------------------------------------------------------------------------------------------------------------------| | | | | | Unaudited Interim Condensed Consolidated Financial Statements | | – | Unaudited Interim Condensed Consolidated Statements of Loss | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss Unaudited Interim Condensed Consolidated Balance Sheets | | ...

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland, Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Update Revenue was $15.8 million, up 5% year-over-year; Constant currency revenue excluding COVID-19 revenue was $16.0 million, up 7% year-ov ...

BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders. "As a research and teaching hospital, as well as a clinical center of excellence, it is our goal to ...

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its oncology testing capabilities through advanced liquid biopsy solutions [1][4] - The partnership with SOPHiA GENETICS aims to leverage cutting-edge technology for rapid validation of genomic panels and sequencing, supporting OncoHelix's mission in precision oncology [3][4] Company Overview - OncoHelix, based in Calgary, Canada, specializes in genomic and molecular testing services globally and collaborates with the Hematology Translational Lab at the University of Calgary [2] - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine, providing the SOPHiA DDM™ platform for analyzing complex genomic data [6] Technology and Innovation - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, analyzing 146 key cancer-associated genes [4] - Liquid biopsy testing offers a less invasive alternative to traditional solid tumor biopsies, extracting cell-free DNA from blood plasma to reveal circulating tumor DNA [3]

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its genomic and molecular testing capabilities [1][8] - The partnership with the Hematology Translational Lab at the University of Calgary has significantly advanced precision oncology and immunology research [1] - Liquid biopsy testing, which extracts cell-free DNA from blood plasma, offers a less invasive alternative to traditional biopsies, facilitating quicker clinical decisions and monitoring [2][9] Company Developments - OncoHelix will utilize the new liquid biopsy solution to enhance its oncology testing capabilities, building on its existing use of the SOPHiA DDM™ Platform for myeloid testing [8][9] - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, focusing on deep sequencing of 146 cancer-associated genes [9] - The implementation of this technology is expected to improve the assessment of cancer treatment responses and the diagnosis of cases where tissue biopsy is not feasible [3][9] Industry Context - SOPHiA GENETICS is a leader in data-driven medicine, utilizing AI to provide actionable insights for healthcare institutions globally [5] - The collaboration between OncoHelix and SOPHiA GENETICS reflects a growing trend in the healthcare industry towards integrating advanced genomic technologies to improve patient care [9]